Compounds > gla 27
Page last updated: 2024-12-08

gla 27

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GLA 27: nonreducing sugar part of lipid A analog with interferon-inducing, tumor necrosis factor-inducing, but not pyrogenic acitivity; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID163574
MeSH IDM0140658

Synonyms (9)

Synonym
gla 27
89756-57-0
[1-[[(2r,3r,4r,5r)-5,6-dihydroxy-1-oxo-4-phosphonooxy-3-tetradecanoyloxyhexan-2-yl]amino]-1-oxotetradecan-3-yl] tetradecanoate
3-o-tetradecanoyl-2n-3-tetradecanoyloxytetradecanoyl-4-o-phosphonoglucosamine
2-deoxy-4-o-phosphono-3-o-tetradecanoyl-2-(3-tetradecanoyloxytetradecanamido)-d-glucose
gla-27
d-glucose, 2-deoxy-2-((1-oxo-3-((1-oxotetradecyl)oxy)tetradecyl)amino)-, 4-(dihydrogen phosphate) 3-tetradecanoate
DTXSID401008960
2-deoxy-2-{[1-hydroxy-3-(tetradecanoyloxy)tetradecylidene]amino}-4-o-phosphono-3-o-tetradecanoylhexose
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (70.00)18.7374
1990's1 (10.00)18.2507
2000's0 (0.00)29.6817
2010's2 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.65 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thymidine
[no description available]		1.9710pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
glucosamine
D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.		1.9710D-glucosamineEscherichia coli metabolite;
geroprotector;
mouse metabolite
lipid a
Lipid A: Lipid A is the biologically active component of lipopolysaccharides. It shows strong endotoxic activity and exhibits immunogenic properties.. lipid A : The glycolipid moiety of bacterial lipopolysaccharide (R can be either hydrogen or a fatty acyl group).		3.68100dodecanoate ester;
lipid A;
tetradecanoate ester		Escherichia coli metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Exacerbation
[description not available]		02.110
Sarcoma, Epithelioid
[description not available]		02.110
Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.		02.110
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		02.0710
Infections, Pseudomonas
[description not available]		02.3820
Vaccinia
The cutaneous and occasional systemic reactions associated with vaccination using smallpox (variola) vaccine.		02.3820
Pseudomonas Infections
Infections with bacteria of the genus PSEUDOMONAS.		02.3820
Experimental Neoplasms
[description not available]		01.9710
Schwartzman Phenomenon
[description not available]		01.9710